COMPANY PROFILE

Genetherapy-ri

Explore full profile

Innovative gene therapies for CNS diseases and monogenic disorders, leveraging AAV vector research

Tokyo, JapanFounded 2014Biotech & Life Sciences

Valuation $250–500M Last recorded · 2025

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Genetherapy-ri

Gene Therapy Research Institution (GTRI) is a pioneering entity in the field of gene therapy, focusing on the development of treatments for central nervous system (CNS) diseases and monogenic disorders. Operating as an academic research hub in Japan, GTRI collaborates with numerous researchers across the country, thanks to the expertise of Dr. Muramatsu, a leading figure in AAV vector research. The institution's primary programs target novel treatments for Sporadic ALS and Parkinson's disease, aiming to bring groundbreaking therapies to clinical practice. GTRI serves a diverse clientele, including academic researchers, medical professionals, and patients suffering from severe neurodegenerative diseases. The company operates in the biotechnology and healthcare market, utilizing a business model that combines research funding, grants, and donations to support its initiatives. Revenue is generated through collaborative research projects, licensing of intellectual property, and potential commercialization of successful therapies.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2014
Headquarters: Tokyo, Japan
Open positions: None listed
Dealroom signal: 18.7/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Neurology, Gene Therapy, Rare Diseases, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

6 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES DOther financing	Apr 2025	$44M	$175M	Undisclosed	—
LATE VCOther financing	Jun 2022	$947K	$3.8M	Undisclosed	—

Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

Genetherapy-ri website traffic

Latest recorded traffic for Genetherapy-ri is 2K monthly website visits, up 5.3% over the last three months.

Latest monthly visits2K 3-month web change+5.3%

Monthly website visitsDec 2022–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ELElisigenAAV gene therapies for neurodegenerative and rare diseases	Seoul, South Korea	Operational	11	$121M	$294M
XBXingaotuo BiotechnologyAAV-mediated gene therapy restoring congenital hearing loss	China	Operational
HTHarness TherapeuticsA private biotechnology company, headquartered in Cambridge-UK, focused on the development of a novel class of therapeutic RNAs	Babraham, United Kingdom	Operational
STSuzhou Huitherapy Biomedical Technology a high-tech enterprise engaged in the industrialization of comprehensively providing nucleic acid drugs	China	Operational
ATAlamab TherapeuticsClinical Trial Approval in Australia	Princeton, United States	Operational
HTHubble TherapeuticsHubble Therapeutics is pioneering novel ion channel gene therapies to restore vision	Hanover, United States	Operational
PBPhageNova BioPioneering Targeted Gene Expression For Cancer and Vaccines	Summit, United States	Operational
TTTeitur TrophicsCyclic peptide therapeutics for neurodegenerative diseases	Aarhus, Denmark	Operational